...
首页> 外文期刊>The Journal of Nuclear Medicine >Hypometabolism Exceeds Atrophy in Presymptomatic Early-Onset Familial Alzheimer's Disease
【24h】

Hypometabolism Exceeds Atrophy in Presymptomatic Early-Onset Familial Alzheimer's Disease

机译:代谢紊乱超过症状前早发家族性阿尔茨海默氏病的萎缩

获取原文
           

摘要

id="p-1">The aim of the present study is to compare brain atrophy with hypometabolism as preclinical markers of Alzheimer's disease (AD) by studying presymptomatic individuals from families with known early-onset autosomal dominant AD (FAD) carrying mutations in the Presenilin 1 gene. >Methods: Seven asymptomatic at-risk FAD individuals (age, 35-49 y; 4 women; education a‰¥ 12 y) and 7 matched healthy control subjects received complete clinical, neuropsychologic, MRI, and 18F-FDG PET examinations. Regions of interest (ROIs: whole brain [WB], hippocampus [Hip], entorhinal cortex [EC], posterior cingulate cortex [PCC], inferior parietal lobule [IPL], and superior temporal gyrus (STG]) were drawn on the MRI scans of all subjects and used to measure volumes on MRI and glucose metabolism (MRglc) from the MRI-coregistered, atrophy-corrected PET scans. >Results: Compared with controls and after correcting for head size, MRI volume reductions in FAD subjects were restricted to the IPL (18%, P 0.02). After atrophy correction and adjusting for pons MRglc, PET MRglc reductions were found in all FAD subjects compared with controls in the WB (13%), bilaterally in the IPL (17%) and in the STG (12%), and in the left EC (21%), PCC (20%), and Hip (12%) (P values 0.05). PET MRglc measurements were consistently less variable than MRI measures, yielding significantly larger effect sizes in separating FAD from controls. >Conclusion: Presymptomatic FAD individuals show widespread MRglc reductions consistent with the typical AD PET pattern in the relative absence of structural brain atrophy. These data further suggest that PET MRglc measures may serve as biomarkers for the preclinical diagnosis of AD.
机译:id =“ p-1”>本研究的目的是通过研究已知早发型常染色体显性AD(FAD)携带者的症状前个体来比较脑萎缩和代谢不足作为阿尔茨海默氏病(AD)的临床前标志物Presenilin 1基因的突变。 >方法: 7名无症状高危FAD患者(年龄35-49岁; 4名妇女;学历≥12岁)和7名匹配的健康对照受试者接受了完整的临床,神经心理学,MRI和< sup> 18 F-FDG PET检查。在MRI上绘制了感兴趣的区域(ROI:全脑[WB],海马[Hip],内嗅皮质[EC],后扣带回皮质[PCC],顶叶小叶[IPL]和颞上回(STG]) >结果:与对照组比较,并在校正了头部大小后,MRI体积被用于对所有受试者进行MRI扫描,并用于测量由MRI共同注册,经萎缩校正的PET扫描中的MRI和葡萄糖代谢(MRglc)量。 FAD受试者的减少仅限于IPL(18%, P <0.02)。在萎缩校正并调整pons MRglc之后,与WB中的对照组相比,所有FAD受试者均发现PET MRglc减少( 13%),双侧IPL(17%)和STG(12%),左EC(21%),PCC(20%)和Hip(12%)( P 值<0.05)。PET MRglc测量始终比MRI测量具有更少的可变性,从而在将FAD与对照组分离中产生了更大的效果。>结论: c FAD个体在相对缺乏结构性脑萎缩的情况下显示出与典型AD PET模式一致的广泛MRglc降低。这些数据进一步表明,PET MRglc措施可作为AD临床前诊断的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号